Hikma Pharmaceuticals Temettü
Temettü kriter kontrolleri 5/6
Hikma Pharmaceuticals is a dividend paying company with a current yield of 3.25% that is well covered by earnings.
Anahtar bilgiler
3.3%
Temettü verimi
0%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | 3.3% |
| Gelecekteki Temettü Verimi | 3.4% |
| Temettü Büyümesi | 11.3% |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | UK£0.790 |
| Ödeme oranı | 61% |
Son temettü güncellemeleri
Recent updates
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24
Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: HIK's dividends per share have been stable in the past 10 years.
Büyüyen Temettü: HIK's dividend payments have increased over the past 10 years.
Piyasaya Karşı Temettü Getirisi
| Hikma Pharmaceuticals Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (HIK) | 3.3% |
| Pazarın Alt %25'i (GB) | 2.1% |
| Pazarın En İyi %25'i (GB) | 5.8% |
| Sektör Ortalaması (Pharmaceuticals) | 2.4% |
| Analist tahmini (HIK) (3 yıla kadar) | 3.4% |
Önemli Temettü: HIK's dividend (3.25%) is higher than the bottom 25% of dividend payers in the UK market (2.1%).
Yüksek Temettü: HIK's dividend (3.25%) is low compared to the top 25% of dividend payers in the UK market (5.79%).
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: With its reasonable payout ratio (61.2%), HIK's dividend payments are covered by earnings.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: With its reasonably low cash payout ratio (46.2%), HIK's dividend payments are well covered by cash flows.